Products

EZScreen™ Donor Specific Antibody detection

Ricimer™ GMSbiotech Analysis software for EZMatch™ & EZScreen™ products

Transfusion Chip - Blood Antigens Genotyping

EZScreen™ Donor Specific Antibody detection

The "EZScreen™" Donor Specific Antibody screening and monitoring test product line will feature HLA Class I & II native antibody detection for pre-& post transplantation.

While traditional markers can aid in diagnosing the clinical status of solid organ transplant recipients, they are generally non-specific and most often only identifiable after graft damage has occurred. The early identification and subsequent removal of clinically harmful Donor Specific Antibodies (DSA) associated with Acute Mediated Rejection (AMR), both pre-& post-transplant may reduce allograft loss and improve patient outcomes.

"EZScreen™" is a sensitive and native state antibody screening and monitoring assay for the accurate detection of DSA for both pre-& post-transplant that is more cost-effective and easily fits into most labs current workflow. This platform is currently in development with Pure Transplant Solutions (PTS) LLC.

Ricimer™ GMSbiotech Analysis software for EZMatch™ & EZScreen™ products

GMSbiotech Ricimer™ software is a companion to GMSbiotech's molecular typing and antibody screening products.

Analysis results can be reviewed in graphical form, allowing easy adjustment of cut-off values to clarify results. Data can be exported or formatted into custom reports. This software runs in both stand-alone (on a single computer) and network environments.

Features & Benefits

  • Supports the most current allele nomenclature format
  • Manually enter reaction patterns
  • Easily update product information (new product and lot information)
  • Compile and print custom reports from your data
  • Export data in multiple formats for use in other systems
  • Compare results to GMSbiotech quality control (QC) data.
  • Automatically notifies user when catalog (.cat)
  • updates are available
  • Use stand alone or in network environment

Transfusion Chip-Blood Antigens Genotyping

Blood group antigens are proteins found on the surface of red cells (erythrocytes) and platelets. They have traditionally been detected by serology in the agglutination test and are clinically very important in transfusion and transplantation. In both fields of medicine, the donor and recipient must have compatible blood group antigens, to avoid alloimmunization and, in the case of organ transplantation, graft rejection. Agglutination for blood typing has been automated and "gel cards" are now widely used in the developed world. However, once the genes encoding red blood cell antigens had been cloned and sequenced genotyping for red blood cell (RBC) antigens became feasible. There are several clinical applications where RBC genotyping has advantages over agglutination for the provision of safe blood. These include: (a) Patients who are recently transfused, (b) Patients who have a positive direct antiglobulin test because of antibodies bound to RBCs: such as in hemolytic anemia, (c) Presence of autoantibodies hinders serological RBC typing but not genotyping, or (d) Patient has a pre-existing clinically significant RBC antibody.

Genotyping is also extremely useful to confirm equivocal results or where there is evidence of weakly expressed antigens. In addition, there are worldwide shortages of 'traditional' grouping antisera that are leading to escalating test costs.

Clearly, there is an unmet need to combine the current understanding of blood group genetics with analytical technologies that would allow such genetics to be implemented, perhaps with field collection, as an inexpensive DNA-based test. We have adapted our microarray technology which was first developed for HLA, the most polymorphic protein and genetic system found in humans to develop the Transfusion Chip. This "Transfusion-Chip" or "T-Chip" for short will enable cost-effective genotyping for ABO, Rh and the other clinically important blood antigens to become the new standard for worldwide DNA-based Blood-Typing, by enabling both clinical and at-home sample collection. GMS technology allows the use of raw blood or cheekswab to carry out this testing.












GMS IP Portfolio

PATENTS: POPULATION SCALE HLA-TYPING AND USE THEREOF

COUNTRY PATENT NO. GRANT DATE EXPIRATION DATE Available Fields of Use
United States of America 7667026 February 23, 2010 February 27, 2027 ALL
United States of America 8,575,325 November 5, 2013 February 18, 2030 ALL
Germany 1991558 November 18, 2015 February 27, 2027 ALL
France 1991558 November 18, 2015 February 27, 2027
United Kingdom 1991558 November 18, 2015 February 27, 2027
Australia 2007313472 May 1, 2014 February 27, 2027
New Zealand 597200 October 1, 2013 February 27, 2027 ALL
New Zealand 571513 June 5, 2012 February 27, 2027 ALL

 

PATENTS: METHODS AND DEVICES BASED UPON A NOVEL FORM OF NUCLEIC ACID DUPLEX ON A SURFACE

COUNTRY PUB. NO. PATENT NO. GRANT DATE EXPIRATION DATE Available Fields of Use
United States of America   7,354,710 April 8, 2008 July 11, 2022 ALL
United States of America   10,272,409 April 30, 2019 July 11, 2022 ALL
United States of America 20190209996       ALL
Australia   2009251843 March 17, 2016 April 3, 2029 ALL
Canada   2,720,460 October 29, 2019 April 3, 2029 ALL
India   300287 August 27, 2018 April 3, 2029 ALL
Japan   6185958 August 23, 2017 May 7, 2035 ALL
Japan   4312595 August 12, 2009 July 11, 2032 ALL

 

PATENTS: METHOD FOR PCR AND HLA-TYPING USING RAW BLOOD

COUNTRY PUB. NO. PATENT NO. GRANT DATE EXPIRATION DATE Available Fields of Use
United States of America   8771951 July 8, 2014 September 24, 2030 ALL
United States of America   10,337,066 July 2, 2019 April 27, 2031 ALL
Australia   2016266065 September 19, 2019 November 16, 2030 ALL
Belgium   2,501,827 December 20, 2017 November 16, 2030 ALL
Canada 2786118       ALL
China   ZL201080060981 January 20, 2016 November 16, 2030 ALL
Germany   2501827 December 20, 2017 November 16, 2030 ALL
European Patent Office 3342880       ALL
France   2501827 December 20, 2017 November 16, 2030 ALL
United Kingdom   2501827 December 20, 2017 November 16, 2030 ALL
Dem. People's Rep. of Korea   10-1953176 February 22, 2019 November 16, 2030 ALL

 

PATENTS: METHOD FOR PCR AND HLA-TYPING USING UNPURIFIED SAMPLES

COUNTRY PUB. NO. PATENT NO. GRANT DATE EXPIRATION DATE Available Fields of Use
United States of America   9416419 August 16, 2016 September 24, 2030 ALL
United States of America 20200080146       ALL

 

PATENT: BLOOD TYPING USING DNA

COUNTRY PUBLICATION NO. Available Fields of Use
Patent Cooperation Treaty WO 2020023484 ALL

 

PATENTS: COMPOSITIONS AND METHODS FOR ENTRAPPING PROTEIN ON A SURFACE

COUNTRY

PATENT NO.

GRANT DATE

EXPIRATION DATE

Available Fields of Use

United States of America 10,556,218 February 11, 2020 May 14, 2034 EXCEPT HLA DIAGNOSTICS
Germany 60 2014 036 584.1 November 21, 2018 May 14, 2034 EXCEPT HLA DIAGNOSTICS
France 2,997,037 November 21, 2018 May 14, 2034 EXCEPT HLA DIAGNOSTICS
United Kingdom 2,997,037 November 21, 2018 May 14, 2034 EXCEPT HLA DIAGNOSTICS
United States of America 9,751,069 September 5, 2017 June 6, 2034 EXCEPT HLA DIAGNOSTICS

 

Licensing opportunities are available for the above patents. Please contact Dr. Krishna Jayaraman.